{"entity":{"id":"nct06767527","kind":"trial","name":"AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer","aka":[],"tldr":"A phase 3 trial of Ivonescimab, Paclitaxel / nab-paclitaxel in triple-negative breast cancer, run by Akeso, now recruiting.","summary":"AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer is a phase 3 interventional study registered as NCT06767527 by Akeso, with 416 participants planned, started 2025-02-07 and due to reach its primary completion in 2026-12. Interventions recorded: AK112, Nab-paclitaxel, Placebo. Conditions listed: Triple-Negative Breast Cancer (TNBC). No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06767527","url":"https://clinicaltrials.gov/study/NCT06767527"}],"tags":["ctgov-ingest"],"related":[],"cancers":["tnbc"],"sections":[],"technologies":[],"targets":[],"drugs":["ivonescimab","paclitaxel"],"companies":["akeso"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06767527","phase":"3","setting":"A Randomized, Controlled, Multi-center Phase III Clinical Study of AK112 Plus Nab-paclitaxel Versus Placebo Plus Nab-paclitaxel as First-line Treatment for Locally Advanced Unresectable or Metastatic Triple-negative Breast Cancer","sponsor":"Akeso","participation":[{"nct":"NCT06767527","source":"https://clinicaltrials.gov/study/NCT06767527","fetchedAt":"2026-10-07T16:55:00.061Z","studySha256":"eb8062f17583e77310662f4b8604ac248005d6a98a275959d017a54254e24aa2","overallStatus":"RECRUITING","lastUpdatePosted":"2026-03-16","leadSponsor":"Akeso","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"75 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":416,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2025-02-07","startedType":"actual","enrolled":416,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06767527/","neighbours":{"cancer":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"drug":[{"id":"ivonescimab","kind":"drug","name":"Ivonescimab","route":"/drugs/ivonescimab/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"}],"company":[{"id":"akeso","kind":"company","name":"Akeso","route":"/companies/akeso/"}]}}